Welcome to our dedicated page for Perimeter Medical Imaging Ai news (Ticker: PYNKF), a resource for investors and traders seeking the latest updates and insights on Perimeter Medical Imaging Ai stock.
Perimeter Medical Imaging AI develops real-time optical coherence tomography imaging systems and artificial-intelligence tools for cancer surgery. The company’s Claire OCT+AI device has FDA premarket approval for intraoperative breast cancer margin assessment, while its S-Series OCT platform provides ultra-high-resolution cross-sectional visualization of excised tissue.
Company news commonly covers FDA regulatory milestones, product demonstrations, commercialization activity, clinical and technology updates, operating and financial results, investor conference presentations, and capital-structure actions such as private placements, warrants, and stock-option matters.
Perimeter Medical Imaging AI, a commercial-stage medical technology company, announced its AI technology is featured in the "Artificial Intelligence: Your Mind & The Machine" exhibit at the Museum of Science & History (MoSH) in Memphis, TN, running until May 6, 2023. The company’s CEO, Jeremy Sobotta, emphasized the significance of their next-gen ultra-high resolution optical imaging technology being evaluated in clinical trials at the West Cancer Center. Supported by AI industry leaders, Perimeter aims to enhance surgical decision-making for cancer patients. The company’s innovative imaging systems are FDA-cleared and are backed by a grant of up to $7.4 million from the Cancer Prevention and Research Institute of Texas.
Perimeter Medical Imaging AI (PYNKF) announced significant leadership changes, appointing Suzanne Foster as the new Chair of the Board of Directors. Effective immediately, her extensive background in healthcare will enhance the company's mission in cancer surgery technology. CEO Jeremy Sobotta expressed confidence in Foster's leadership, praising her experience within the organization. Former Chair Dr. Anthony Holler remains as a director. Additionally, Chris Scott resigned as CFO, with Russell Wagner stepping in as Interim CFO while a search for Scott’s replacement begins. Perimeter aims to leverage its advanced imaging technology to improve patient outcomes.
Perimeter Medical Imaging AI (TSX-V: PINK, OTC: PYNKF) announced the completion of two additional installations of its S-Series OCT system at the end of 2022, successfully doubling its commercial installed base during Q4. CEO Jeremy Sobotta emphasized the momentum in their business, particularly within a major healthcare system, enhancing the value perceived by early users. This expansion aims to improve patient outcomes and reduce healthcare costs in the U.S.
Perimeter Medical Imaging AI (PYNKF) announced a peer-reviewed study published in JAMA Otolaryngology—Head and Neck Surgery validating its wide-field Optical Coherence Tomography (WF-OCT) technology for real-time margin visualization in head and neck surgeries. The study involved 53 patients with squamous cell carcinoma, demonstrating that WF-OCT can potentially improve surgical outcomes without disrupting existing workflows. CEO Jeremy Sobotta highlighted the importance of this innovative imaging technology, which correlates well with histological results.
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK, OTC: PYNKF) announced its third-quarter financial results for 2022, highlighting key developments in its clinical trials and commercial placements. The company activated eight clinical trial sites for its B-Series OCT system with ImgAssist AI and received FDA approval for further expansion. Operating expenses rose to $5.94 million, while the net loss improved to $818,527 compared to $3.88 million in Q3 2021. Cash and cash equivalents stood at $43.2 million as of September 30, 2022.
CEO Jeremy Sobotta expressed optimism regarding ongoing trials and commercial adoption amid challenging conditions.
Perimeter Medical Imaging AI, Inc. (PYNKF) announced a successful commercial placement of its Perimeter S-Series OCT system at a second hospital within a major healthcare network in North Texas. This follows a prior placement within the same network and underscores Perimeter's strategy to expand its technology in integrated delivery systems. CEO Jeremy Sobotta highlighted positive feedback from end-users and stakeholders, indicating strong market validation for their advanced imaging tools aimed at transforming cancer surgery.
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK, OTC: PYNKF) will announce its Q3 2022 financial results on November 15, 2022, after U.S. market close. A conference call is scheduled for the same day at 5:00 PM ET, featuring CEO Jeremy Sobotta and CFO Chris Scott. The call will be accessible via dial-in and webcast, with details available on the Company's website. Perimeter focuses on innovative imaging solutions for cancer surgery, aiming to enhance surgical outcomes.
Perimeter Medical Imaging AI, Inc. (PYNKF) announces the results of its 2022 annual and special meeting of shareholders held on October 27, 2022. Shareholders approved all matters, including the election of seven board members and a new omnibus equity incentive plan. The Omnibus Plan allows the issuance of options and units, capping at 12,834,531 common shares. Additionally, KPMG LLP was reappointed as the company’s auditor for the upcoming year. Perimeter focuses on innovative imaging tools to enhance cancer surgery, with promising products currently in evaluation.
Perimeter Medical Imaging AI (OTC:PYNKF) announced significant findings at the College of American Pathologists Annual Meeting 2022. Their research highlights the use of the Perimeter S-Series Wide-Field Optical Coherence Tomography (OCT) system for real-time microstructural imaging across various tissues, including breast, kidney, and lung. Presentations addressed the intraoperative evaluation of tissue in head and neck surgery, supporting the device's potential to enhance surgical outcomes. The device offers 10x greater resolution than X-ray and 100x that of MRI, aligning with the company's mission to improve cancer surgery.
Perimeter Medical Imaging AI announced its graduation from a Tier 2 Issuer to a Tier 1 Issuer on the TSX Venture Exchange, effective October 5, 2022. This upgrade reflects the Company’s significant financial resources and sustainable business model, with cash and cash equivalents totaling $44,966,273 as of June 30, 2022. The transition allows for the release of 5,080,959 shares from escrow, better positioning Perimeter for growth in the medical imaging sector.